Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 3,793–3,800 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Sanofi SARCLISA (isatuximab) - (IMROZ) Multiple myeloma not eligible for transplant Phase 3 Ongoing Intravenous Oncology
Sanofi DUPIXENT (dupilumab) - (CUPID STUDY C) Chronic Spontaneous Urticaria (CSU) Phase 3 Data Released Subcutaneous Immunology
Sanofi KEVZARA (sarilumab) Coronavirus COVID-19 Phase 3 Trial Discontinued Subcutaneous COVID-19
Sanofi KEVZARA (sarilumab) Coronavirus COVID-19 Phase 3 Trial Discontinued Subcutaneous COVID-19
Sanofi LIBTAYO (cemiplimab) Non-small cell lung cancer (NSCLC) Phase 3 Trial Discontinued intravenous Oncology
Sanofi Amcenestrant - (AMEERA-5) ER+/HER2- advanced breast cancer Phase 3 Trial Discontinued Oral Oncology
Sanofi PRV-031 (teplizumab) - (PROTECT) Recent Onset Type 1 Diabetes Phase 3 Ongoing Intravenous Endocrinology
Sanofi SARCLISA (isatuximab) - (IMROZ) Multiple myeloma not eligible for transplant Phase 3 Ongoing Intravenous Oncology